Skip to content

N. Farber

3 papers in the library · 99 citations · publishing 2021-2023

Papers

Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression

Psychopharmacology January 22, 2021 J. Siegel, B. Palanca, B. Ances et al. 53 citations

A single 96-hour infusion of ketamine, co-administered with clonidine, is well tolerated and produces a rapid and sustained antidepressant response in over 50% of adults with treatment-resistant depression. In an open-label study of 23 adults, depressive symptoms dropped markedly from an average MADRS score of 29 at baseline to 9 one day after infusion, and remained reduced at 2 weeks (13) and 8 weeks (15). Brain imaging showed that the infusion normalized overconnectivity in the limbic system and between the subgenual anterior cingulate cortex and the default mode network, with response-dependent and treatment-dependent connectivity changes.

Intravenous Ketamine for Late-Life Treatment-Resistant Depression: A Pilot Study of Tolerability, Safety, Clinical Benefits, and Effect on Cognition

The American journal of geriatric psychiatry December 1, 2022 H. Oughli, M. A. Gebara, A. Ciarleglio et al. 33 citations

Repeated intravenous ketamine infusions are well-tolerated and associated with improvements in depression and executive function in older adults aged 60 and older with treatment-resistant depression. In a pilot trial, 25 participants received ketamine twice weekly for four weeks, with partial responders continuing weekly infusions for four more weeks. Completion rates were high (88% acute, 100% continuation), with no serious adverse events or discontinuations due to side effects. Transient blood pressure elevation, dissociation, and craving occurred but were manageable. Depressive symptoms improved significantly, with 48% of participants responding. Executive function and overall fluid cognition also improved (Cohen's d = 0.61) and were sustained.

Change in patient‐centered outcomes of psychological well‐being, sleep, and suicidality following treatment with intravenous ketamine for late‐life treatment‐resistant depression

International Journal of Geriatric Psychiatry July 1, 2023 Benjamin Vanderschelden, M. A. Gebara, H. Oughli et al. 13 citations

Among older adults with treatment-resistant depression, intravenous ketamine treatment was associated with improvements in psychological well-being and sleep, but not in suicidality. The findings suggest that ketamine may enhance aspects of mental health beyond depressive symptoms in this population, though its effect on suicidal thoughts remains unclear.